The optimal management of patients with ACS is an ever-evolving process; clinical experience and practice often outpace guidelines. Watch Drs Bohm, Camm, Fox, Mehta, and Connolly address the state-of-the-art management of ACS and the role of antiplatelets in ACS and beyond.
As the COURAGE debate rages on, PCI and DES next tackle bypass surgery in patients with diabetes, multivessel disease and left main lesions. From ESC in Munich, Dr Boden joins SYNTAX investigators Drs Mohr and Serruys to discuss PCI and CABG in complex patients given the SYNTAX findings.
What's the latest on the use of drug-eluting stents in "complex" patients? Join our international panel of experts, Drs Feldman, Kappetein, Mack, and Morice as they discuss the challenges of treating patients with complex lesions - what evidence do we have now and what can we expect to see in the near future?
Bleeding in ACS patients has been associated with increased adverse cardiac events and negative patient outcomes. Join Drs Gilles Montalescot and Johanne Silvain as they discuss a case of bleeding and review treatment strategies to improve outcomes and minimize adverse events for these patients.
Just when you thought it was safe to go back into the cath lab, COURAGE roars again. In light of quality of life data showing that the early benefits for PCI are lost at two to three years, Drs Kandzari and Popma discuss how to optimally manage patients with stable angina.
Traditionally, Latin American countries have had lower rates of PCI and DES use compared with Europe and the US. Recorded at SOLACI 2008, Dr Leon leads an information exchange on PCI north and south of the border with Drs Abizaid, Belardi, Echeverri and Lopez-Cuellar.
Current guidelines for thienopyridines in PCI note the lack of RCT data for higher loading doses. Read Dr Wang's lowdown on loading doses, including recent presentations from the 2008 SCAI-ACCi2 meeting. Then watch Drs Mehta and Mehran discuss where CURRENT-OASIS-7 will fit in.
Given the success of PCI, the transcatheter management of cardiac disease has expanded into new frontiers. The area of valvular intervention has rapidly evolved in recent years. Dr Philipp Bonhoeffer, a pioneer in the field, discusses current and future developments in the percutaneous management of valvular disease.
In March 2008, USA Today proclaimed that "Angioplasty's golden era may be fading." Not so fast, say interventional cardiologists in light of positive data for DES vs BMS, and the efficacy of PCI in complex settings. Drs Hamm, Rothman and Waksman discuss the state of DES/PCI in the US and Europe.
The incremental cost of DES versus BMS is balanced by reduced restenosis and improved quality of life. What level of stent thrombosis tips the scale back in favor of BMS? Join Drs Cohen and Bhatt as they discuss decision analysis data that tackles these questions.
Now you see it, now you don't. Could bioabsorbable stents be the answer to late stent thrombosis or will acute recoil and restenosis prove to be their Achilles heel? Eric Topol reviews the data on the bioabsorbable stents in development and gives his opinion on the likelihood of the disappearing stent becoming a reality.
Join Dr Gregg Stone as he presents the most comprehensive DES/BMS meta-analysis ever! Expert faculty Drs Hermiller, Moses, Popma and Turco also debate current DES safety and efficacy data.
If we're all looking at the same data, why do the European and US guidelines for the treatment of ACS differ in terms of initiation, dosing, and choices of pharmacological therapies? Drs Ohman, Montalescot, Pollack and Fox discuss the similarities and differences.
One year post COURAGE, what's hot in the world of interventional cardiology? Dr Jeffrey Popma gives his take on the top stories from the 2008 ACC and SCAI-ACCi2 scientific sessions.
2008 will bring two new DES to the US market. Combined with recent reassuring data on long-term outcomes, will next-generation devices kick-start a comeback for DES? Drs Topol and Teirstein discuss these issues and make predictions for PCI in 2008.
Over the past year, much debate has been given to the issue of drug-eluting stents (DES) and the risk of restenosis. Trials like COURAGE enrolled patients with chronic stable angina and looked to examine optimal medical therapy versus an invasive strategy. Despite much lively discussion surrounding the results of COURAGE, questions still linger regarding the use of invasive (DES or BMS) versus OMT and what treatment is best for patients with coronary heart disease. This program addresses these issues in an evidence-based manner. Please join Drs Feldman, Kereiakes, Davidson and Farkouh as they untangle recent clinical trial data.
Does the search for a "safer" stent minimize the need for a more "efficacious" one? Does increasing safety heighten efficacy? Will stent safety be enhanced by longer duration of antiplatelet therapy? Join our esteemed faculty as they debate these questions.
Who should be receiving coronary PCI? Who should be performing PCI? What are the best strategies - for doctor and patient - regarding management of peripheral arterial occlusions? Join our faculty for a stimulating and thought-provoking conversation regarding these issues.
Drug-eluting stents (DESs) have become state of the art interventional therapy for the treatment of coronary vessel occlusion. To date, over 9 million DES devices have been placed. While DESs are designed to minimize the incidence of restenosis, late stent thrombosis appears to be problematic. This program will present the evolution of DES therapy, define late stent thrombosis, and describe current research that will take us to the next level with DES technology.
As the COURAGE debate rages on, PCI and DES next tackle bypass surgery in patients with diabetes, multivessel disease and left main lesions. From ESC in Munich, Dr Boden joins SYNTAX investigators Drs Mohr and Serruys to discuss PCI and CABG in complex patients given the SYNTAX findings.
Bleeding in ACS patients has been associated with increased adverse cardiac events and negative patient outcomes. Join Drs Gilles Montalescot and Johanne Silvain as they discuss a case of bleeding and review treatment strategies to improve outcomes and minimize adverse events for these patients.
What's the latest on the use of drug-eluting stents in "complex" patients? Join our international panel of experts, Drs Feldman, Kappetein, Mack, and Morice as they discuss the challenges of treating patients with complex lesions - what evidence do we have now and what can we expect to see in the near future?
Join Dr Gregg Stone as he presents the most comprehensive DES/BMS meta-analysis ever! Expert faculty Drs Hermiller, Moses, Popma and Turco also debate current DES safety and efficacy data.
The optimal management of patients with ACS is an ever-evolving process; clinical experience and practice often outpace guidelines. Watch Drs Bohm, Camm, Fox, Mehta, and Connolly address the state-of-the-art management of ACS and the role of antiplatelets in ACS and beyond.
Current guidelines for thienopyridines in PCI note the lack of RCT data for higher loading doses. Read Dr Wang's lowdown on loading doses, including recent presentations from the 2008 SCAI-ACCi2 meeting. Then watch Drs Mehta and Mehran discuss where CURRENT-OASIS-7 will fit in.